Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- sars-cov-2 (covid-19) chadox1 vaccine, recombinant
- teplizumab
Interactions between your drugs
SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant teplizumab
Applies to: sars-cov-2 (covid-19) chadox1 vaccine, recombinant, teplizumab
ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.
MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.
References (1)
- (2022) "Product Information. Tzield (teplizumab)." Provention Bio, Inc.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Paxlovid
PAXLOVID (nirmatrelvir with ritonavir) is an antiviral medication used to treat COVID-19. Includes ...
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Tyenne
Tyenne is approved to treat adults with moderately to severely active rheumatoid arthritis, Giant ...
Olumiant
Olumiant is used to treat rheumatoid arthritis, alopecia areata (hair loss), and COVID-19. Includes ...
Anakinra
Anakinra is used for COVID-19, cryopyrin-associated periodic syndromes, interleukin-1 receptor ...
Baricitinib
Baricitinib (brand name Olumiant) is used to treat rheumatoid arthritis, alopecia areata (hair ...
Molnupiravir
Molnupiravir is an experimental medicine being studied for the treatment of mild-to-moderate ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.